^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BRCA1 mutation

    i
    Entrez ID:
    672
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Related tests:
    Apply
    Use of an Ultra-rapid BRCA1/2 Status Screening Test in Theranostic Indication: Performance and Interest for Patients and Practitioners (TURBO) (NCT06111417)
    Phase N/A
    Centre Georges Francois Leclerc
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    06/12/2024
    Primary completion :
    06/12/2026
    Completion :
    08/12/2026
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery (NCT03317405)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    10/31/2018
    Primary completion :
    02/22/2021
    Completion :
    08/16/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Zonalta (Z-endoxifen hydrochloride)
    PLATFORM Study of Precision Medicine for Rare Tumors (NCT04423185)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/15/2020
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    EGFR • HER-2 • BRAF • ALK • MET • BRCA1 • BRCA2 • KIT • ROS1 • CDKN2A
    |
    BRCA2 mutation • BRCA1 mutation • EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • MET amplification • KIT mutation • ALK fusion • ROS1 fusion • CDKN2A mutation • MET mutation • BRAF amplification
    |
    Xalkori (crizotinib) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • imatinib • Tyvyt (sintilimab) • Alecensa (alectinib) • Zejula (niraparib) • Irene (pyrotinib) • Ameile (aumolertinib) • Vizimpro (dacomitinib)
    Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (NRG-GY023) (NCT04739800)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/10/2021
    Primary completion :
    01/26/2023
    Completion :
    06/14/2025
    PD-L1 • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (NCT05457257)
    Phase 4
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/29/2022
    Primary completion :
    10/22/2024
    Completion :
    09/30/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone
    Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors (BGB-290-102) (NCT03333915)
    Phase 1/2
    BeiGene
    Completed
    Last update posted :
    02/04/2025
    Initiation :
    12/21/2016
    Primary completion :
    08/24/2020
    Completion :
    08/11/2021
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Partruvix (pamiparib)
    Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NRG-GY021) (NCT04034927)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    12/04/2019
    Primary completion :
    07/31/2021
    Completion :
    09/18/2025
    BRCA1 • BRCA2 • BRCA • MUC16
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Imjudo (tremelimumab-actl)
    Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy (SOLO-2) (NCT01874353)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/03/2013
    Primary completion :
    09/19/2016
    Completion :
    12/31/2025
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • cisplatin
    Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD) (NCT02000622)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    01/20/2025
    Initiation :
    03/27/2014
    Primary completion :
    12/09/2016
    Completion :
    12/31/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • capecitabine • Halaven (eribulin mesylate)
    Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib (BAROCCO) (NCT03314740)
    Phase 2
    Mario Negri Institute for Pharmacological Research
    Completed
    Last update posted :
    01/10/2025
    Initiation :
    06/12/2017
    Primary completion :
    04/01/2021
    Completion :
    04/01/2021
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • paclitaxel • Recentin (cediranib)
    Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort) (PROpelSub) (NCT05171816)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    01/03/2025
    Initiation :
    06/24/2021
    Primary completion :
    01/22/2024
    Completion :
    04/28/2026
    HRD
    |
    BRCA1 mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects (NCT03248570)
    Phase 2
    University of California, San Francisco
    Completed
    Last update posted :
    11/20/2024
    Initiation :
    02/20/2018
    Primary completion :
    09/28/2023
    Completion :
    09/28/2023
    BRCA1 • BRCA2 • MSI • BRCA
    |
    BRCA1 mutation
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel
    Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation (NCT02953457)
    Phase 2
    Roswell Park Cancer Institute
    Completed
    Last update posted :
    11/19/2024
    Initiation :
    06/29/2017
    Primary completion :
    09/15/2021
    Completion :
    08/15/2024
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer (NCT04673448)
    Phase 1
    University of Washington
    Recruiting
    Last update posted :
    11/08/2024
    Initiation :
    10/18/2021
    Primary completion :
    12/31/2025
    Completion :
    03/30/2026
    HER-2 • PD-L1 • ER • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Zejula (niraparib) • Jemperli (dostarlimab-gxly)
    Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROPEL) (NCT03732820)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    10/08/2024
    Initiation :
    10/31/2018
    Primary completion :
    07/30/2021
    Completion :
    11/04/2024
    HRD
    |
    BRCA1 mutation
    |
    Lynparza (olaparib) • abiraterone acetate
    Trial of Olaparib in Combination with AZD5363 (ComPAKT) (NCT02338622)
    Phase 1
    Royal Marsden NHS Foundation Trust
    Completed
    Last update posted :
    09/26/2024
    Initiation :
    03/31/2014
    Primary completion :
    03/21/2016
    Completion :
    03/21/2017
    BRCA1 • BRCA2 • PARP1
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Truqap (capivasertib)
    Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA) (NCT02032823)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    08/23/2024
    Initiation :
    04/22/2014
    Primary completion :
    03/27/2020
    Completion :
    05/28/2029
    HER-2 • PGR • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative • PGR positive
    |
    Lynparza (olaparib)
    Efficacy of Olaparib in Advanced Cancers Occurring in Patients With Germline Mutations or Somatic Tumor Mutations in Homologous Recombination Genes (1-2018 BSMO) (NCT03967938)
    Phase 2
    AZ-VUB
    Active, not recruiting
    Last update posted :
    08/19/2024
    Initiation :
    02/07/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib)
    Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis (NCT03047135)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    03/01/2017
    Primary completion :
    05/24/2023
    Completion :
    05/01/2025
    BRCA1 • BRCA2 • ATM • CDK12 • CHEK2 • RAD51B • BRIP1 • RAD51C • RAD51D • CHEK1 • BARD1 • FANCL • PPP2R2A
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51B mutation • BARD1 mutation • CHEK1 mutation • CHEK1 expression
    |
    Lynparza (olaparib)
    Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer (NCT05922930)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    10/11/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    BRCA1 • BRCA2 • TACSTD2
    |
    BRCA2 mutation • BRCA1 mutation • TROP2 expression
    |
    cyclophosphamide • fludarabine IV • TROP2-CAR-NK
    Clinical Trial of PM54 in Advanced Solid Tumors Patients. (NCT05841563)
    Phase 1
    PharmaMar
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    04/28/2023
    Primary completion :
    03/01/2026
    Completion :
    03/01/2026
    BRAF • BRCA1 • BRCA2
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type
    |
    PM54
    Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk (NCT00043472)
    Phase N/A
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    06/14/2024
    Initiation :
    07/09/2003
    BRCA1 • BRCA2 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation
    Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study (NCT05287451)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/10/2022
    Primary completion :
    12/26/2026
    Completion :
    12/26/2026
    BRCA1 • BRCA2 • BRIP1 • RAD51C • RAD51D
    |
    BRCA2 mutation • BRCA1 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • RAD51 mutation
    M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCI 9938) (NCT02595931)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    07/22/2016
    Primary completion :
    03/07/2023
    Completion :
    12/05/2024
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • PALB2 mutation
    |
    irinotecan • berzosertib (M6620)
    Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... (NCT02484404)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    06/29/2015
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    EGFR • HER-2 • BRAF • ALK • PGR • BRCA1 • BRCA2
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • ALK translocation • BRCA1 mutation + BRCA2 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    Early Assessment of Ovarian Cancer Aggressiveness by Metabolic Imaging (NCT05866679)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/12/2024
    Primary completion :
    08/31/2026
    Completion :
    08/31/2028
    BRCA1 • BRCA2 • MSH2
    |
    BRCA2 mutation • BRCA1 mutation
    Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (LUNG-MAP Sub-Study) (NCT03845296)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    04/16/2019
    Primary completion :
    01/01/2022
    Completion :
    07/01/2024
    EGFR • BRAF • ALK • BRCA1 • BRCA2 • ROS1 • HRD • BRCA • CD4
    |
    BRAF V600E • BRCA2 mutation • BRCA1 mutation • EGFR mutation • BRAF V600 • EGFR T790M • HRD • ALK fusion • ROS1 fusion • HRD + BRCA1 mutation
    |
    Rubraca (rucaparib)
    A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors (NCT04991480)
    Phase 1
    Artios Pharma Ltd
    Active, not recruiting
    Last update posted :
    06/03/2024
    Initiation :
    09/13/2021
    Primary completion :
    03/01/2025
    Completion :
    08/01/2025
    HER-2 • BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HER-2 negative
    |
    Talzenna (talazoparib) • Zejula (niraparib) • ART4215
    Pancreatic Cancer Early Detection Program (PCEDP) (NCT02206360)
    Phase N/A
    White Plains Hospital
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2014
    Primary completion :
    03/01/2024
    Completion :
    06/01/2024
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype (HERO) (NCT05574673)
    Phase N/A
    Nordic Society of Gynaecological Oncology - Cli...
    Recruiting
    Last update posted :
    05/24/2024
    Initiation :
    12/01/2022
    Primary completion :
    12/01/2028
    Completion :
    12/01/2028
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation • HRD
    Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer (MITO-RT3/RAD) (NCT04593381)
    Phase N/A
    Gemelli Molise Hospital
    Completed
    Last update posted :
    05/23/2024
    Initiation :
    03/01/2021
    Primary completion :
    12/31/2023
    Completion :
    12/31/2023
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer (COCOS) (NCT02502266)
    Phase 2/3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/21/2024
    Initiation :
    05/03/2016
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    BRCA1 • BRCA2 • BRCA • MUC16
    |
    BRCA2 mutation • BRCA1 mutation • BRCA mutation
    |
    Lynparza (olaparib) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin) • doxorubicin liposomal
    Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer (NCT03337087)
    Phase 1/2
    Academic and Community Cancer Research United
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/02/2018
    Primary completion :
    03/31/2021
    Completion :
    08/09/2025
    BRCA1 • BRCA2 • HRD • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • HRD • PALB2 mutation • HRD + BRCA1 mutation
    |
    5-fluorouracil • Rubraca (rucaparib) • leucovorin calcium • Onivyde (nanoliposomal irinotecan) • fluorouracil topical
    Genetic Testing for Men With Metastatic Prostate Cancer (GENTleMEN) (NCT03503097)
    Phase N/A
    University of Washington
    Active, not recruiting
    Last update posted :
    05/13/2024
    Initiation :
    08/21/2017
    Primary completion :
    08/21/2024
    Completion :
    08/21/2024
    BRCA1 • HRD
    |
    BRCA1 mutation • HRD • ATM mutation
    Prophylactic Salpingectomy With Delayed Oophorectomy (NCT01907789)
    Phase N/A
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/10/2024
    Initiation :
    08/26/2013
    Primary completion :
    12/31/2030
    Completion :
    12/31/2030
    BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation
    Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer (OlympiaN) (NCT05498155)
    Phase 2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    05/09/2024
    Initiation :
    11/07/2022
    Primary completion :
    05/02/2024
    Completion :
    12/31/2026
    HER-2 • ER • BRCA1 • BRCA2 • BRCA
    |
    BRCA2 mutation • BRCA1 mutation • ER negative • BRCA mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer (NCT05617755)
    Phase 1
    Arsenal Biosciences, Inc.
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    11/29/2022
    Primary completion :
    12/01/2024
    Completion :
    02/01/2027
    BRCA1 • BRCA2 • MUC16
    |
    BRCA2 mutation • BRCA1 mutation
    |
    cyclophosphamide • AB-1015
    Response to PARP Inhibitor Predicted by the RAD51 Assay (REPAIR) (NCT03044795)
    Phase 2
    University Medical Center Groningen
    Withdrawn
    Last update posted :
    05/03/2024
    Initiation :
    11/01/2019
    Primary completion :
    11/01/2020
    Completion :
    11/01/2020
    ER • BRCA1 • BRCA2 • BRCA • MUC16 • RAD51 • IL2
    |
    BRCA2 mutation • BRCA1 mutation
    |
    veliparib (ABT-888)
    A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk) (NCT04251052)
    Phase N/A
    NRG Oncology
    Recruiting
    Last update posted :
    05/02/2024
    Initiation :
    09/01/2020
    Primary completion :
    06/23/2036
    Completion :
    06/23/2037
    BRCA1 • MUC16
    |
    BRCA1 mutation
    Pancreatic Cancer Genetics (NCT01102569)
    Phase N/A
    Columbia University
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    01/01/2008
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    BRCA1 • BRCA2
    |
    BRCA2 mutation • BRCA1 mutation